Kronos Bio, Inc. (KRON)

Kronos Bio Statistics

Total Valuation

Kronos Bio has a market cap or net worth of $55.47 million. The enterprise value is -$47.21 million.

Market Cap	55.47M
Enterprise Value	-47.21M

Important Dates

The last earnings date was Wednesday, November 13, 2024, after market close.

Earnings Date	Nov 13, 2024
Ex-Dividend Date	n/a

Share Statistics

Kronos Bio has 60.29 million shares outstanding. The number of shares has increased by 3.93% in one year.

Current Share Class	60.29M
Shares Outstanding	60.29M
Shares Change (YoY)	+3.93%
Shares Change (QoQ)	+0.35%
Owned by Insiders (%)	28.81%
Owned by Institutions (%)	32.73%
Float	42.92M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.19
Forward PS	n/a
PB Ratio	0.47
P/TBV Ratio	0.47
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.32, with a Debt / Equity ratio of 0.23.

Current Ratio	8.32
Quick Ratio	8.12
Debt / Equity	0.23
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-46.83

Financial Efficiency

Return on equity (ROE) is -59.08% and return on invested capital (ROIC) is -28.26%.

Return on Equity (ROE)	-59.08%
Return on Assets (ROA)	-25.13%
Return on Capital (ROIC)	-28.26%
Revenue Per Employee	$156,571
Profits Per Employee	-$1.36M
Employee Count	63
Asset Turnover	0.05
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -22.52% in the last 52 weeks. The beta is 1.86, so Kronos Bio's price volatility has been higher than the market average.

Beta (5Y)	1.86
52-Week Price Change	-22.52%
50-Day Moving Average	0.94
200-Day Moving Average	1.05
Relative Strength Index (RSI)	41.97
Average Volume (20 Days)	173,286

Short Selling Information

The latest short interest is 527,682, so 0.88% of the outstanding shares have been sold short.

Short Interest	527,682
Short Previous Month	674,525
Short % of Shares Out	0.88%
Short % of Float	1.23%
Short Ratio (days to cover)	8.81

Income Statement

In the last 12 months, Kronos Bio had revenue of $9.86 million and -$85.59 million in losses. Loss per share was -$1.44.

Revenue	9.86M
Gross Profit	9.86M
Operating Income	-78.02M
Pretax Income	-102.85M
Net Income	-85.59M
EBITDA	-76.23M
EBIT	-78.02M
Loss Per Share	-$1.44

Balance Sheet

The company has $124.86 million in cash and $25.80 million in debt, giving a net cash position of $99.06 million or $1.64 per share.

Cash & Cash Equivalents	124.86M
Total Debt	25.80M
Net Cash	99.06M
Net Cash Per Share	$1.64
Equity (Book Value)	111.13M
Book Value Per Share	1.84
Working Capital	112.54M

Cash Flow

In the last 12 months, operating cash flow was -$77.62 million and capital expenditures -$31,000, giving a free cash flow of -$77.66 million.

Operating Cash Flow	-77.62M
Capital Expenditures	-31,000
Free Cash Flow	-77.66M
FCF Per Share	-$1.29

Margins

Gross Margin	100.00%
Operating Margin	-790.92%
Pretax Margin	-867.66%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-1,047.33%

Dividends & Yields

Kronos Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.93%
Shareholder Yield	-3.93%
Earnings Yield	-165.05%
FCF Yield	-149.76%

Analyst Forecast

The average price target for Kronos Bio is $1.63, which is 77.17% higher than the current price. The consensus rating is "Buy".

Price Target	$1.63
Price Target Difference	77.17%
Analyst Consensus	Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	112.16%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Kronos Bio has an Altman Z-Score of -5.06 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-5.06
Piotroski F-Score	3